Literature DB >> 30046638

Tuberculosis and Leprosy Coinfection: A Perspective on Diagnosis and Treatment.

Lisa Mangum1, Dustin Kilpatrick2, Barbara Stryjewska3, Rahul Sampath4.   

Abstract

Both leprosy and tuberculosis (TB) are known to have similar geographic endemicity. In the setting of coinfection, interferon-gamma release assays (IGRAs) to detect latent TB can be falsely positive. We report a case of leprosy with a positive IGRA and asymptomatic active pulmonary TB. Minocycline and dapsone therapy was initiated during the workup for TB and changed to rifampin (Rif), isoniazid, pyrazinamide, and ethambutol, with the addition of dapsone once coinfection was confirmed. Our review of the literature revealed a preponderance of coinfection reported with borderline and lepromatous disease. Ten patients were diagnosed with leprosy as the first infection; 7 of these patients (70%) were treated with Rif before TB diagnosis, and 70% (7/10) of coinfected patients were on steroids. If treatment for leprosy is a consideration before ruling out active TB, then minocycline may temporarily replace the Rif. The dire implications of Rif monotherapy in undiagnosed coinfection may warrant chest radiography with or without sputum microbiology as routine initial workup for all leprosy cases.

Entities:  

Keywords:  coinfection; leprosy; resistance; steroids; tuberculosis

Year:  2018        PMID: 30046638      PMCID: PMC6054147          DOI: 10.1093/ofid/ofy133

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


Both leprosy and tuberculosis (TB) are known to have similar geographic endemicity [1, 2], and TB needs to be ruled out in cases of leprosy before treatment is initiated with rifampin (Rif)-based regimens. The use of protein-based interferon-gamma release assays (IGRAs) to test for latent TB is confounded by the cross-reactivity of T-cell response with the protein homologs in Mycobacterium leprae [3, 4]. The Purified Protein Derivative (PPD) skin test may have some utility in the diagnosis of latent TB in the setting of paucibacillary leprosy (PBL); however, “giant reactions” to PPD testing have been documented in mono-infection with multibacillary leprosy (MBL) [5, 6].

CASE REPORT

A 32-year-old Marshallese woman presented with osteomyelitis of the left third distal phalanx, multiple burn wounds on both hands (Figure 1), and hypopigmented skin lesions (Figure 2) with reduced thermal sensation for several months. A limited disarticulation of the distal phalanx and slit skin smears of hypopigmented skin were performed at the National Hansen’s Institute. The smears were Fite stain negative for acid fast bacilli (AFB); however, polymerase chain reaction (PCR) was positive for M. leprae. Initial TB workup showed a positive IGRA and PPD skin test greater than 15 mm, and chest radiography (CXR) showed a subtle infiltrate in the right middle lobe, raising suspicion for active TB despite lack of respiratory symptoms. The patient’s sputum was AFB smear negative but culture positive for drug-susceptible TB. During the above workup for TB, minocycline and dapsone therapy was initiated for 2 months and was changed to Rif, isoniazid (INH), pyrazinamide, ethambutol (RIPE therapy) with the addition of dapsone once sputum cultures were reported. Repeat sputum cultures after 1 month of RIPE therapy were negative for TB, and RIPE therapy was consolidated to INH and Rif after 2 months. INH, Rif, and dapsone were continued for 4 months, after which the patient was considered effectively treated for TB. The patient was then placed back on minocycline and dapsone for an additional 4 months, completing a 1-year treatment course for leprosy. One month into therapy, CXR was normal, and at the completion of therapy, she had improvement in skin lesions and overall sense of well-being. The patient did not experience any immunological reactions during the above therapy.
Figure 1.

Left hand: burn injury, skin lesions, Fite stain negative, polymerase chain reaction positive for Mycobacterium leprae.

Figure 2.

Hypo-aesthetic, hypopigmented lesions on the patient’s back.

Left hand: burn injury, skin lesions, Fite stain negative, polymerase chain reaction positive for Mycobacterium leprae. Hypo-aesthetic, hypopigmented lesions on the patient’s back.

DISCUSSION

In the past 15 years, 13 cases of TB and leprosy coinfection have been published; they are summarized in the Table 1. A preponderance of coinfection was seen with borderline and lepromatous disease cases. The immunological milieu of the host appears to paradoxically influence susceptibility to mycobacterial coinfection, with no consensus regarding whether prior exposure to one offers protection or predisposition to the other. On one end of the spectrum, impaired cell-mediated immunity [7, 8] in patients with MBL may predispose to TB coinfection, whereas among immunocompetent contacts of patients with Hansen’s disease in Brazil, the presence of a Bacillus Calmette-Guerin vaccination scar offered 98% protection against MBL [9].
Table 1.

Summary of reported cases for coinfection of Leprosy and Tuberculosis within last 15 years

Year/AuthorAgeSexType of LeprosyFirst Infection/TX Given for LeprosyGap of DxPast Hx of TBType of TBX-Ray/PPD/InterferonSputumDx of LeprosyRisk FactorsLepra Rxn
2003/Lee et al. [13]62-MBLTB6 moNAPulmCXR abnormalAFB+Histochem-Fite- Farco, slit skin smearNAType I
2007/Seeramareddy et al. Case #1 [14]65-MLLLeprosy/Dapsone Clofazimine Rifampin3 moNoPulmPleural effusions, CXR w/ infiltrateAFB+NASteroidNo
2007/Seeramareddy et al. Case #2 [14]50-MLLLeprosy/Thailomide Clofazimine Prednisone22 moNAPulm & PeritCXR cavitary lesionsAFB+NASteroidType II
2010/Prasad et al. [15]34-MBLLeprosy/ Dapsone Clofazimine Rifampin11 moNoPulmCXR, cavitary lesions, PPD 22 mmAFB+Slit skin smearSteroidType II
2013/Trindale et al. Case #1 [16]31-MBB-BT TB6 moNAPleuralPPD 14 mm, pleural effusion, CXR abnormalNAHisotchem-Fite- Farco stainNAType I
2013/Trindale et al. Case #2 [16]46-FBB-BTLeprosy/Thailomide Clofazimine Prednisone1 moNAPulmPPD 10 mm, CT chest opacitiesAFB+Hisotchem with anti-BCGSteroidType I
2014/Choubey et al. [17]34-MLLTB½ moNoPulmCXR w/ patchy infiltratesAFB+Slit skin smearNANA
2014/Rawson et al. [18] Case #118-MLLLeprosy/Dapsone Clofazimine Rifampin9 moNoPulmNAAFB+Slit skin smearSteroidSilent Neuritis
2014/Rawson et al. [18] Case #238-MLLLeprosy/Dapsone Clofazimine Rifampin3 yNoExtra-Pulm (CNS)NAPCRSlit skin smearSteroidType II
2014/Rawson et al. [18] Case #346-MLLLeprosy/Dapsone Clofazimine Rifampin11 moNoPulmNAAFB+Slit skin smearNoNo
2015/Sendrasoa et al. [19]49-MLLLeprosy/Dapsone Clofazimine Rifampin17 moNoPulmCT chest opacitiesAFB+Histochem- slit skin smear, PCR biopsySteroidType II
2015/Verma et al. [20]38-MBLLeprosy/Dapsone Clofazimine Rifampin7 moNoPulmCXR cavitary lesionsAFB+Skin smearNAType II
2017/present author33-FTLLeprosy/Mino Dapsone2 moNoPulmCXR opacities, Interferon Gold positiveAFB+PCR biopsyNANo

Abbreviations: AFB, Acid Fast Bacilli; BB-BT, mid-borderline/borderline tuberculoid leprosy; BL, lepromatous borderline leprosy; CXR, chest radiography; LL, lepromatous leprosy; Mino, minocycline; NA, data not available; Neuro, neuritis; PCR, polymerase chain reaction; Perit, peritoneal; PPD, purified protein derivative; Pulm, pulmonary; TB, tuberculosis; TL, tuberculoid leprosy.

Summary of reported cases for coinfection of Leprosy and Tuberculosis within last 15 years Abbreviations: AFB, Acid Fast Bacilli; BB-BT, mid-borderline/borderline tuberculoid leprosy; BL, lepromatous borderline leprosy; CXR, chest radiography; LL, lepromatous leprosy; Mino, minocycline; NA, data not available; Neuro, neuritis; PCR, polymerase chain reaction; Perit, peritoneal; PPD, purified protein derivative; Pulm, pulmonary; TB, tuberculosis; TL, tuberculoid leprosy. From a treatment perspective, the US Department of Health and Human Services recommends daily Rif [10] in combination with other drugs for the treatment of leprosy across the spectrum. An undiagnosed coinfected patient runs the risk of receiving Rif monotherapy and developing resistance during therapy [11]. In our review, 10 patients were diagnosed with leprosy as the first infection, and of these 10, 7 patients (70%) were treated with Rif before diagnosing TB. Seven of the 10 patients (70%) mentioned above were on steroids before the diagnosis of TB, suggesting that steroids may be a risk factor for reactivation of TB. However, in the TRIPOD studies, no incidence of TB was seen among 300 patients over 24 months who were on prednisone and multidrug therapy for Hansens [12].

CONCLUSION

The clinical implications of failure to identify coinfection cannot be understated, and a positive IGRA or PPD test in a patient with Leprosy should not be considered false positive without ruling out active TB. Rif is a vital component in the treatment regimen for both TB and leprosy, and if treatment for leprosy is a consideration before ruling out active TB, then minocycline may temporarily replace Rif. The dire implications of Rif monotherapy in undiagnosed TB and leprosy coinfection may warrant a CXR with or without sputum microbiology as routine initial workup for all leprosy cases. Additionally, steroid use may be a risk factor for coinfection.

Acknowledgments

No authors contributing to the publication of this paper have any conflicts of interest or funding sources to report. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
  15 in total

1.  Concomitant pulmonary tuberculosis and leprosy.

Authors:  Han N Lee; Colleen S Embi; Karen M Vigeland; Clifton R White
Journal:  J Am Acad Dermatol       Date:  2003-10       Impact factor: 11.527

2.  Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance.

Authors:  M Lipsitch; B R Levin
Journal:  Int J Tuberc Lung Dis       Date:  1998-03       Impact factor: 2.373

3.  Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis.

Authors:  Annemieke Geluk; Krista E van Meijgaarden; Kees L M C Franken; Yanri W Subronto; Brigitte Wieles; Sandra M Arend; Elizabeth P Sampaio; Tjitske de Boer; William R Faber; Ben Naafs; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 4.  Leprosy and tuberculosis concomitant infection: a poorly understood, age-old relationship.

Authors:  Timothy Miles Rawson; Vaseem Anjum; Jasmin Hodgson; A Kameswara Rao; Krishna Murthy; P S S Sundar Rao; Jonnalagada Subbanna; P V Ranganadha Rao
Journal:  Lepr Rev       Date:  2014-12       Impact factor: 0.537

5.  Concomittant pulmonary tuberculosis and borderline leprosy with type-II lepra reaction in single patient.

Authors:  Rajendra Prasad; Sanjay Kumar Verma; Rajni Singh; Giridhar Hosmane
Journal:  Lung India       Date:  2010-01

6.  Giant reactions to tuberculin in lepromatous leprosy patients.

Authors:  M F Waters; J L Stanford
Journal:  Int J Lepr Other Mycobact Dis       Date:  1985-12

7.  Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis.

Authors:  A Geluk; K E van Meijgaarden; K L M C Franken; B Wieles; S M Arend; W R Faber; B Naafs; T H M Ottenhoff
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

8.  Elevated serum CCL2 concomitant with a reduced mycobacterium-induced response leads to disease dissemination in leprosy.

Authors:  Z Hasan; B Jamil; I Zaidi; S Zafar; A A Khan; R Hussain
Journal:  Scand J Immunol       Date:  2006-03       Impact factor: 3.487

9.  Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials.

Authors:  Jan H Richardus; Stephen G Withington; Alison M Anderson; Richard P Croft; Peter G Nicholls; Wim H Van Brakel; W Cairns S Smith
Journal:  Lepr Rev       Date:  2003-12       Impact factor: 0.537

10.  Development of giant reaction in response to PPD skin test in lepromatous leprosy patients.

Authors:  E P Sampaio; N C Duppre; J A Nery; A L Moreira; E N Sarno
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-06
View more
  4 in total

1.  Concurrent pulmonary tuberculosis and lepromatous leprosy in a newly diagnosed HIV positive patient: a case report.

Authors:  Josiah T Masuka; Zamambo Mkhize; Somasundram Pillay; Anisa Mosam
Journal:  BMC Pulm Med       Date:  2021-06-30       Impact factor: 3.317

Review 2.  Examining the Complex Relationship Between Tuberculosis and Other Infectious Diseases in Children.

Authors:  Elizabeth Whittaker; Elisa López-Varela; Claire Broderick; James A Seddon
Journal:  Front Pediatr       Date:  2019-06-25       Impact factor: 3.418

3.  Leprosy stigma & the relevance of emergent therapeutic options.

Authors:  Kabir Sardana; Ananta Khurana
Journal:  Indian J Med Res       Date:  2020-01       Impact factor: 2.375

4.  Mycobacterium leprae transmission characteristics during the declining stages of leprosy incidence: A systematic review.

Authors:  Thomas Hambridge; Shri Lak Nanjan Chandran; Annemieke Geluk; Paul Saunderson; Jan Hendrik Richardus
Journal:  PLoS Negl Trop Dis       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.